These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9578571

  • 1. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123.
    Shapiro R.
    Biochemistry; 1998 May 12; 37(19):6847-56. PubMed ID: 9578571
    [Abstract] [Full Text] [Related]

  • 2. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41.
    Holloway DE, Chavali GB, Hares MC, Baker MD, Subbarao GV, Shapiro R, Acharya KR.
    Biochemistry; 2004 Feb 10; 43(5):1230-41. PubMed ID: 14756559
    [Abstract] [Full Text] [Related]

  • 3. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis.
    Harper JW, Vallee BL.
    Biochemistry; 1989 Feb 21; 28(4):1875-84. PubMed ID: 2719939
    [Abstract] [Full Text] [Related]

  • 4. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2).
    Teufel DP, Kao RY, Acharya KR, Shapiro R.
    Biochemistry; 2003 Feb 18; 42(6):1451-9. PubMed ID: 12578357
    [Abstract] [Full Text] [Related]

  • 5. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
    Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K, Acharya KR.
    J Mol Biol; 1999 Jan 22; 285(3):1209-33. PubMed ID: 9918722
    [Abstract] [Full Text] [Related]

  • 6. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
    Shapiro R, Ruiz-Gutierrez M, Chen CZ.
    J Mol Biol; 2000 Sep 15; 302(2):497-519. PubMed ID: 10970748
    [Abstract] [Full Text] [Related]

  • 7. Mutagenesis of residues flanking Lys-40 enhances the enzymatic activity and reduces the angiogenic potency of angiogenin.
    Harper JW, Fox EA, Shapiro R, Vallee BL.
    Biochemistry; 1990 Aug 07; 29(31):7297-302. PubMed ID: 1698454
    [Abstract] [Full Text] [Related]

  • 8. Structural determinants of the uridine-preferring specificity of RNase PL3.
    Vicentini AM, Kote-Jarai Z, Hofsteenge J.
    Biochemistry; 1996 Jul 16; 35(28):9128-32. PubMed ID: 8703917
    [Abstract] [Full Text] [Related]

  • 9. A single amino acid substitution changes ribonuclease 4 from a uridine-specific to a cytidine-specific enzyme.
    Hofsteenge J, Moldow C, Vicentini AM, Zelenko O, Jarai-Kote Z, Neumann U.
    Biochemistry; 1998 Jun 30; 37(26):9250-7. PubMed ID: 9649305
    [Abstract] [Full Text] [Related]

  • 10. Alteration of the enzymatic specificity of human angiogenin by site-directed mutagenesis.
    Curran TP, Shapiro R, Riordan JF.
    Biochemistry; 1993 Mar 09; 32(9):2307-13. PubMed ID: 8095159
    [Abstract] [Full Text] [Related]

  • 11. Identification of small-molecule inhibitors of human angiogenin and characterization of their binding interactions guided by computational docking.
    Jenkins JL, Shapiro R.
    Biochemistry; 2003 Jun 10; 42(22):6674-87. PubMed ID: 12779322
    [Abstract] [Full Text] [Related]

  • 12. Residues 36-42 of liver RNase PL3 contribute to its uridine-preferring substrate specificity. Cloning of the cDNA and site-directed mutagenesis studies.
    Vicentini AM, Hemmings BA, Hofsteenge J.
    Protein Sci; 1994 Mar 10; 3(3):459-66. PubMed ID: 8019417
    [Abstract] [Full Text] [Related]

  • 13. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
    Chen CZ, Shapiro R.
    Proc Natl Acad Sci U S A; 1997 Mar 04; 94(5):1761-6. PubMed ID: 9050852
    [Abstract] [Full Text] [Related]

  • 14. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
    Chen CZ, Shapiro R.
    Biochemistry; 1999 Jul 20; 38(29):9273-85. PubMed ID: 10413501
    [Abstract] [Full Text] [Related]

  • 15. Guest-host crosstalk in an angiogenin-RNase A chimeric protein.
    Holloway DE, Shapiro R, Hares MC, Leonidas DD, Acharya KR.
    Biochemistry; 2002 Aug 20; 41(33):10482-9. PubMed ID: 12173935
    [Abstract] [Full Text] [Related]

  • 16. Replacing a surface loop endows ribonuclease A with angiogenic activity.
    Raines RT, Toscano MP, Nierengarten DM, Ha JH, Auerbach R.
    J Biol Chem; 1995 Jul 21; 270(29):17180-4. PubMed ID: 7615514
    [Abstract] [Full Text] [Related]

  • 17. Genetic selection for critical residues in ribonucleases.
    Smith BD, Raines RT.
    J Mol Biol; 2006 Sep 22; 362(3):459-78. PubMed ID: 16920150
    [Abstract] [Full Text] [Related]

  • 18. Altering substrate specificity of phosphatidylcholine-preferring phospholipase C of Bacillus cereus by random mutagenesis of the headgroup binding site.
    Antikainen NM, Hergenrother PJ, Harris MM, Corbett W, Martin SF.
    Biochemistry; 2003 Feb 18; 42(6):1603-10. PubMed ID: 12578373
    [Abstract] [Full Text] [Related]

  • 19. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
    Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM.
    Biochemistry; 1996 Jan 16; 35(2):545-53. PubMed ID: 8555226
    [Abstract] [Full Text] [Related]

  • 20. Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency.
    Leonidas DD, Shapiro R, Subbarao GV, Russo A, Acharya KR.
    Biochemistry; 2002 Feb 26; 41(8):2552-62. PubMed ID: 11851402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.